Hepion 10-Q: Going Concern, $3.1M Raise, and New COO
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals filed its 10-Q, reporting a going concern warning, a $3.1 million private placement, and new executive appointments.
Key Events · Earnings and Guidance · CTRVP
-
Going Concern Warning
The company has substantial doubt about its ability to continue as a going concern within one year, with only $1.6 million in cash as of June 30, 2026.
-
$3.1M Private Placement Closed
The July 2026 Offering closed on August 3, 2026, issuing 61.1 million shares and warrants at $0.05 per share for gross proceeds of approximately $3.1 million.
-
New Day License Terminated
On July 22, 2026, the company terminated its license agreement with New Day Diagnostics, with New Day returning 346,020 shares of common stock.
-
New COO Appointed
Sireesh Appajosyula was appointed Chief Operating Officer effective August 1, 2026, with a base salary of $220,000 and a $50,000 sign-on bonus.
Analysis · CTRVP · Life Sciences
The quarterly report confirms Hepion remains a going concern with only $1.6 million in cash as of June 30, 2026, and discloses the closing of a $3.1 million private placement on August 3, 2026. The filing also reveals the termination of the New Day Diagnostics license agreement and the appointment of a new COO, adding governance and strategic context to the company's survival efforts.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.